tag:blogger.com,1999:blog-4201808194301598766Mon, 07 Oct 2024 03:53:33 +0000Press ReleaseNewsPatent2008 AGM2008 First Quarter ResultsAnnual ReportCancer Research Reovirus ReolysinInterviewREO 011RecruitingResultsSEC Filingshttp://oncolytics.blogspot.com/noreply@blogger.com (Author)Blogger75125tag:blogger.com,1999:blog-4201808194301598766.post-4668534624886006687Wed, 13 Aug 2008 00:55:00 +00002008-08-12T17:57:28.507-07:00Press ReleaseCALGARY, AB, --- August 12, 2008 - Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY) announced today that the U.S. National Cancer Institute (NCI), part of the National Institutes of Health, has started enrolment in a Phase 2 clinical trial for patients with metastatic melanoma using systemic administration of REOLYSIN®, Oncolytics’ proprietary formulation of the human reovirus. The http://oncolytics.blogspot.com/2008/08/us-nci-starts-enrolment-in-phase-2.htmlnoreply@blogger.com (Author)22tag:blogger.com,1999:blog-4201808194301598766.post-885203829402272838Wed, 30 Jul 2008 12:53:00 +00002008-07-30T06:04:53.307-07:00Press ReleaseCALGARY, July 29 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced its financial results and highlights for the three and six month periods ended June 30, 2008."Oncolytics experienced a strong second quarter with the reporting of durable clinical responses to REOLYSIN® combination therapy treatment in refractory head and neck cancer patients," http://oncolytics.blogspot.com/2008/07/oncolytics-biotech-inc-announces-2008.htmlnoreply@blogger.com (Author)0tag:blogger.com,1999:blog-4201808194301598766.post-8451942060564012630Thu, 17 Jul 2008 17:59:00 +00002008-07-17T11:02:40.109-07:00Press ReleaseOk, so this is a few days late, but I think most of you should have known about this already.Monday July 14, 4:22 pm ET- Company to Host Conference Call to Update Clinical Program -CALGARY, July 14Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has now enrolled and treated 200 cancer patients in clinical studies with Reolysin®, its proprietary formulation ofhttp://oncolytics.blogspot.com/2008/07/oncolytics-biotech-inc-treats-200th.htmlnoreply@blogger.com (Author)0tag:blogger.com,1999:blog-4201808194301598766.post-4788916301771567587Tue, 24 Jun 2008 21:38:00 +00002008-06-24T14:42:49.897-07:00NewsInteresting article worth checking out from McClatchy Newspapers.Viruses aren't always the bad guys. Sure, they can cause colds, measles, AIDS and other miseries. But with some tinkering, these tiny organisms may become a new and better way to treat cancer....researchers are working with a harmless virus that sits in the lungs and intestines of most people. It's called a "reovirus," short for http://oncolytics.blogspot.com/2008/06/article-in-cancer-war-viruses-can-be.htmlnoreply@blogger.com (Author)0tag:blogger.com,1999:blog-4201808194301598766.post-6273423094323215261Fri, 20 Jun 2008 06:47:00 +00002008-06-19T23:51:14.682-07:00Press ReleaseCALGARY, June 20 - Oncolytics Biotech Inc. ("Oncolytics") announced today that following U.S. Food and Drug Administration (FDA) review, the Company is initiating a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN® in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers. The Principal Investigator is Dr. Monica Mita of the Cancer http://oncolytics.blogspot.com/2008/06/oncolytics-biotech-inc-announces-us.htmlnoreply@blogger.com (Author)0tag:blogger.com,1999:blog-4201808194301598766.post-5961666942896314359Thu, 12 Jun 2008 18:27:00 +00002008-06-12T11:30:00.425-07:00Press ReleaseCALGARY, June 12 - Oncolytics Biotech Inc., announced today that Dr. Brad Thompson, President and CEO of Oncolytics, will participate in two separate presentations at the BIO 2008 International Convention.Dr. Thompson is scheduled to provide a corporate overview of the Company on Tuesday, June 17th at 3:30 p.m. PT at the BIO Business Forum.On Wednesday, June 18th at 4:00 p.m. PT, Dr. Thompson is http://oncolytics.blogspot.com/2008/06/oncolytics-biotech-inc-to-present-at.htmlnoreply@blogger.com (Author)0tag:blogger.com,1999:blog-4201808194301598766.post-7001385140963112841Wed, 11 Jun 2008 04:11:00 +00002008-06-10T21:21:03.948-07:00Press ReleaseCALGARY, June 10 - Oncolytics Biotech Inc. ("Oncolytics") announced today that patient enrolment has started in a Phase 1/2 clinical trial for patients with metastatic ovarian, peritoneal and fallopian tube cancers using concurrent intravenous (IV) and intraperitoneal (IP) administration of REOLYSIN®, Oncolytics' proprietary formulation of the human reovirus. The National Cancer Institute (NCI), http://oncolytics.blogspot.com/2008/06/oncolytics-biotech-inc-announces-start.htmlnoreply@blogger.com (Author)0tag:blogger.com,1999:blog-4201808194301598766.post-6357467758239996211Tue, 10 Jun 2008 05:11:00 +00002008-06-09T22:16:58.049-07:00SEC FilingsOncolytics Biotech, Inc. filed Form F-10 with the United States Securities and Exchange Commision. See the text here.http://oncolytics.blogspot.com/2008/06/oncolytics-biotech-inc-files-form-f-10.htmlnoreply@blogger.com (Author)0tag:blogger.com,1999:blog-4201808194301598766.post-3463534591875994249Tue, 10 Jun 2008 05:07:00 +00002008-06-09T22:10:15.309-07:00Press ReleaseCALGARY, Canada, June 5 -- Oncolytics Biotech Inc. ("Oncolytics") announced today that that it has started patient enrolment in a Phase II clinical trial using intravenous administration of REOLYSIN® in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers. The principal investigator is Dr. Kevin Harrington of The Institute of Cancer Research and The Royal http://oncolytics.blogspot.com/2008/06/oncolytics-biotech-starts-patient.htmlnoreply@blogger.com (Author)0tag:blogger.com,1999:blog-4201808194301598766.post-6073483162271466059Mon, 02 Jun 2008 07:39:00 +00002008-06-02T00:49:11.953-07:00Press ReleaseCALGARY, Canada, June 2/Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced that interim results of a Phase II study of intravenous REOLYSIN® in patients with sarcomas metastatic to the lung were presented yesterday at the American Society of Clinical Oncology (ASCO) annual meeting. The presentation, entitled "A Phase II Study of Intravenous REOLYSIN (Wild-type Reovirus) in the Treatment http://oncolytics.blogspot.com/2008/06/oncolytics-biotech-inc-collaborators.htmlnoreply@blogger.com (Author)0tag:blogger.com,1999:blog-4201808194301598766.post-3489195681045426981Thu, 29 May 2008 01:15:00 +00002008-05-28T18:17:23.898-07:00Press ReleaseCALGARY, May 26/Dr. Matt Coffey, Chief Scientific Officer of Oncolytics Biotech Inc. will present an update on the clinical development of Reolysin at the 4th Canadian Gene Therapy and Vaccines Symposium on Tuesday, May 27 at 10:00 a.m. (ET). The symposium is being held at the National Research Council's Biotechnology Research Institute in Montreal, Quebec on May 26th and 27th, 2008.http://oncolytics.blogspot.com/2008/05/oncolytics-biotech-inc-to-present-at.htmlnoreply@blogger.com (Author)0tag:blogger.com,1999:blog-4201808194301598766.post-3826126719438944379Thu, 29 May 2008 01:13:00 +00002008-05-28T18:15:05.316-07:00Press ReleaseCALGARY, May 23/Oncolytics Biotech Inc. today announced it has been granted Canadian Patent 2,360,833 entitled "Reovirus for the Treatment of Cellular Proliferative Disorders." The claims describe the use of one or more recombinant reoviruses to treat Ras-mediated proliferative disorders."This patent provides the Company with additional patent protection for the use of reovirus compositions for http://oncolytics.blogspot.com/2008/05/oncolytics-biotech-inc-announces_28.htmlnoreply@blogger.com (Author)0tag:blogger.com,1999:blog-4201808194301598766.post-9206258937912110403Thu, 29 May 2008 01:10:00 +00002008-05-28T18:13:15.452-07:00Press ReleaseCALGARY, May 22/Oncolytics Biotech Inc. announced today that it has successfully transferred cGMP production for REOLYSIN® at the 40-litre batch size to SAFC Pharma(TM), a Division of Sigma-Aldrich Corporation. This follows the successful scale-up from 20 litres to 40 litres announced by the Company last year. Yields at the 40-litre scale should provide sufficient doses to support future http://oncolytics.blogspot.com/2008/05/oncolytics-biotech-inc-transfers-40.htmlnoreply@blogger.com (Author)0tag:blogger.com,1999:blog-4201808194301598766.post-5914982710863381343Thu, 29 May 2008 01:09:00 +00002008-05-28T18:10:41.887-07:00A few older news releases.http://oncolytics.blogspot.com/2008/05/getting-caught-up.htmlnoreply@blogger.com (Author)0tag:blogger.com,1999:blog-4201808194301598766.post-3227615837258229966Tue, 20 May 2008 14:23:00 +00002008-05-20T07:24:52.073-07:00PatentPress ReleaseOncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced that it has been granted U.S. Patent 7,374,752 entitled "Reovirus for the Treatment of Cellular Proliferative Disorders." The claims cover pharmaceutical compositions which comprise various recombinant reoviruses."This patent provides the Company with additional patent protection for reovirus compositions in the http://oncolytics.blogspot.com/2008/05/oncolytics-biotech-inc-announces_20.htmlnoreply@blogger.com (Author)0tag:blogger.com,1999:blog-4201808194301598766.post-3801594226329112416Fri, 16 May 2008 17:28:00 +00002008-05-16T10:50:52.149-07:00Press ReleaseOncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that an abstract covering interim results of a Phase II study of intravenous REOLYSIN® in patients with sarcomas metastatic to the lung is available on the American Society of Clinical Oncology (ASCO) website at www.asco.org and on the Oncolytics website at www.oncolyticsbiotech.com. The abstract is entitled "A Phase II Study of http://oncolytics.blogspot.com/2008/05/oncolytics-biotech-inc-collaborators-to.htmlnoreply@blogger.com (Author)0tag:blogger.com,1999:blog-4201808194301598766.post-5014042904070089383Wed, 14 May 2008 13:49:00 +00002008-05-14T06:54:05.729-07:00Press ReleaseCALGARY, AB, --- May 14, 2008 - Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY) announced today that that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for its Clinical Trial Application (CTA) to begin a Phase II clinical trial using intravenous administration of REOLYSIN® in combination with paclitaxel and carboplatin http://oncolytics.blogspot.com/2008/05/oncolytics-biotech-inc-announces-uk.htmlnoreply@blogger.com (Author)0tag:blogger.com,1999:blog-4201808194301598766.post-4993013961885138436Fri, 09 May 2008 19:45:00 +00002008-05-09T12:48:24.956-07:00Press ReleaseCALGARY, May 9 - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has begun patient enrolment in a clinical trial using intravenous administration of REOLYSIN® in combination with cyclophosphamide, a chemotherapeutic agent as well as immune modulator, in patients with advanced cancers. The Principal Investigators are Dr. James Spicer of King's College in http://oncolytics.blogspot.com/2008/05/oncolytics-biotech-inc-starts-patient.htmlnoreply@blogger.com (Author)0tag:blogger.com,1999:blog-4201808194301598766.post-5036647464777313330Mon, 05 May 2008 13:27:00 +00002008-05-05T06:32:43.334-07:00Press ReleaseOncolytics Biotech Inc. announced today that its 2008 Annual and Special Meeting of the Shareholders will be held on Wednesday, May 7, 2008 at 9:00 a.m. (ET) at the Yale Club of New York City, 50 Vanderbilt Ave, New York.Following the business portion of the meeting, Dr. Brad Thompson, President and CEO of Oncolytics, will discuss recent progress in developing REOLYSIN® as a potential cancer http://oncolytics.blogspot.com/2008/05/oncolytics-biotech-inc-announces.htmlnoreply@blogger.com (Author)1tag:blogger.com,1999:blog-4201808194301598766.post-3933802840657222756Sat, 03 May 2008 23:52:00 +00002008-05-03T16:58:16.365-07:002008 AGMThe 2008 Annual and Special Meeting webcast will be held this Wednesday, May 7th at 9:30 am ET. Listen to the webcast here.http://oncolytics.blogspot.com/2008/05/agm-webcast.htmlnoreply@blogger.com (Author)0tag:blogger.com,1999:blog-4201808194301598766.post-3173627665052269275Thu, 01 May 2008 01:22:00 +00002008-04-30T18:32:47.775-07:002008 First Quarter ResultsPress ReleaseOncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY) today announced its financial results and highlights for the three month period ended March 31, 2008.“We are currently enrolling or recruiting patients in a total of nine clinical trials, four exploring the use of REOLYSIN® as a monotherapy, and five exploring the use of REOLYSIN® in combination with a variety of chemotherapies, immunehttp://oncolytics.blogspot.com/2008/04/oncolytics-biotech-inc-announces-2008.htmlnoreply@blogger.com (Author)0tag:blogger.com,1999:blog-4201808194301598766.post-8099901473650750223Wed, 23 Apr 2008 17:57:00 +00002008-04-23T11:16:17.669-07:00Oncolytics Biotech announced the publication of the first study that shows that the reovirus directly activates human dendritic cells, and that reovirus-activated dendritic cells stimulate innate killing by natural killer cells and T cells. This suggests a new potential role for T cells in oncolytic virus-induced local tumor cell death.Read the press release here or below.Oncolytics Biotech Inc.http://oncolytics.blogspot.com/2008/04/new-article-published-in-journal-of.htmlnoreply@blogger.com (Author)0tag:blogger.com,1999:blog-4201808194301598766.post-761822683860902827Thu, 17 Apr 2008 22:05:00 +00002008-04-17T15:14:57.173-07:00Viral Therapy in Treating Patients With Metastatic MelanomaRATIONALE: Viral therapy may be able to kill tumor cells without damaging normal cells.PURPOSE: This phase II trial is studying the side effects and how well viral therapy works in treating patients with metastatic melanoma.OBJECTIVES:PrimaryTo assess the antitumor effect of wild-type reovirus (Reolysin®), in terms of tumor response rate http://oncolytics.blogspot.com/2008/04/clinicaltrialsgov-updated-now.htmlnoreply@blogger.com (Author)0tag:blogger.com,1999:blog-4201808194301598766.post-1770195821925757781Thu, 17 Apr 2008 01:13:00 +00002008-04-16T18:17:13.554-07:00NewsLOS ANGELES (April 15, 2008) – A common, naturally occurring virus that attacks cancer cells but appears to be harmless to normal cells is being studied as a possible treatment for malignant, highly aggressive and deadly brain tumors called gliomas. Researchers at Cedars-Sinai Medical Center are among a few in the United States evaluating this experimental therapy.Read more here.For more http://oncolytics.blogspot.com/2008/04/article-cedars-sinai-medical-center.htmlnoreply@blogger.com (Author)0tag:blogger.com,1999:blog-4201808194301598766.post-3594795498392904800Wed, 16 Apr 2008 13:39:00 +00002008-04-16T06:42:05.436-07:00Press ReleaseOncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that Prof. Alan Melcher and his research group at St. James's University Hospital in Leeds, U.K. published the results of their work in the April 10 online issue of Gene Therapy. The paper is entitled "Inflammatory Tumour Cell Killing by Oncolytic Reovirus for the Treatment of Melanoma."The investigators showed that http://oncolytics.blogspot.com/2008/04/oncolytics-biotech-inc-announces-gene.htmlnoreply@blogger.com (Author)0